FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311754209> ?p ?o ?g. }

• W4311754209 abstract "Abstract Background The inodilator levosimendan has shown improved outcomes in acute heart failure (AHF) and cardiac surgery. Its hemodynamic effect is persistent, owing to a long (70-80 hours) elimination half-life of its active metabolites. No robust data is available of the use of levosimendan in patients with severe renal failure (SRF), thus its use is contraindicated in patients with estimated glomerular filtration rate (eGFR≤30 mL/min). Hypothesis Different pharmacokinetics due to renal failure may alter levosimendan active metabolites elimination, causing more pronounced hemodynamic effects. We aimed to characterize the hemodynamic effect of levosimendan in a real-world cohort of SRF patients. Methods We reviewed patients who received levosimendan (12.5 mg) for AHF or cardiogenic shock in our CICU (N=132), excluding those without invasive hemodynamics (n=85), and those without data before and during levosimendan infusion (n=11), a total of 36 patients were finally included in this analysis. We compared hemodynamics before and during levosimendan infusion in the study cohort with CKD-EPI eGFR≤30 mL/min/1.73 m2 or CRRT and those without. Results Patients with low eGFR (n=11) were older, they had similar LVEF and invasive hemodynamics before levosimendan infusion to the higher eGFR cohort. Visual inspection of the LOESS regression plots (Figure) revealed an higher drop in mean arterial pressure (MAP) and diastolic arterial pressure (DAP) in the low eGFR cohort. The maximum drop was observed at day 4 from levosimendan initiation, invasive hemodynamics at this timepoint revealed a lower DAP (44.6±8.8 vs 62.6±11.9 mmHg; p=0.014) and a tendentially lower MAP (73.6±5.5 vs 84.4±11.5 mmHg; p=0.079) while systolic arterial pressure (125.0±24.6 vs 121.3±21.8 mmHg; p=0.779), cardiac index (2.1±0.5 vs 2.5±0.7 L/m2; p=0.211), and mean pulmonary arterial pressure (25.8±8.3 vs 24.8±9.6 mmHg; p=0.844) did not differ between groups. In-hospital death was not different in the two cohorts (27.3 vs 16.0%; p=0.650). Conclusions Patient with eGFR≤30 mL/min/1.73 m2 demonstrated a higher drop in DAP and MAP four days after levosimendan infusion start, without impact on hospital mortality. These findings may suggest a more pronounced hemodynamic effect of levosimendan in patients with SRF, possibly due to altered pharmacokinetics of its active metabolites." @default.
• W4311754209 created "2022-12-28" @default.
• W4311754209 creator A5000595448 @default.
• W4311754209 creator A5016891339 @default.
• W4311754209 creator A5032550420 @default.
• W4311754209 creator A5048502162 @default.
• W4311754209 creator A5057253215 @default.
• W4311754209 creator A5066490384 @default.
• W4311754209 creator A5081860805 @default.
• W4311754209 creator A5085972611 @default.
• W4311754209 creator A5089129845 @default.
• W4311754209 creator A5089333699 @default.
• W4311754209 date "2022-12-14" @default.
• W4311754209 modified "2023-10-16" @default.
• W4311754209 title "824 HEMODYNAMIC EFFECTS OF LEVOSIMENDAN IN PATIENTS WITH ACUTE HEART FAILURE AND SEVERE RENAL FAILURE" @default.
• W4311754209 doi "https://doi.org/10.1093/eurheartjsupp/suac121.001" @default.
• W4311754209 hasPublicationYear "2022" @default.
• W4311754209 type Work @default.
• W4311754209 citedByCount "0" @default.
• W4311754209 crossrefType "journal-article" @default.
• W4311754209 hasAuthorship W4311754209A5000595448 @default.
• W4311754209 hasAuthorship W4311754209A5016891339 @default.
• W4311754209 hasAuthorship W4311754209A5032550420 @default.
• W4311754209 hasAuthorship W4311754209A5048502162 @default.
• W4311754209 hasAuthorship W4311754209A5057253215 @default.
• W4311754209 hasAuthorship W4311754209A5066490384 @default.
• W4311754209 hasAuthorship W4311754209A5081860805 @default.
• W4311754209 hasAuthorship W4311754209A5085972611 @default.
• W4311754209 hasAuthorship W4311754209A5089129845 @default.
• W4311754209 hasAuthorship W4311754209A5089333699 @default.
• W4311754209 hasBestOaLocation W43117542091 @default.
• W4311754209 hasConcept C126322002 @default.
• W4311754209 hasConcept C159641895 @default.
• W4311754209 hasConcept C164705383 @default.
• W4311754209 hasConcept C178853913 @default.
• W4311754209 hasConcept C2776850375 @default.
• W4311754209 hasConcept C2777335384 @default.
• W4311754209 hasConcept C2778198053 @default.
• W4311754209 hasConcept C500558357 @default.
• W4311754209 hasConcept C71924100 @default.
• W4311754209 hasConceptScore W4311754209C126322002 @default.
• W4311754209 hasConceptScore W4311754209C159641895 @default.
• W4311754209 hasConceptScore W4311754209C164705383 @default.
• W4311754209 hasConceptScore W4311754209C178853913 @default.
• W4311754209 hasConceptScore W4311754209C2776850375 @default.
• W4311754209 hasConceptScore W4311754209C2777335384 @default.
• W4311754209 hasConceptScore W4311754209C2778198053 @default.
• W4311754209 hasConceptScore W4311754209C500558357 @default.
• W4311754209 hasConceptScore W4311754209C71924100 @default.
• W4311754209 hasIssue "Supplement_K" @default.
• W4311754209 hasLocation W43117542091 @default.
• W4311754209 hasOpenAccess W4311754209 @default.
• W4311754209 hasPrimaryLocation W43117542091 @default.
• W4311754209 hasRelatedWork W2022452358 @default.
• W4311754209 hasRelatedWork W2039772027 @default.
• W4311754209 hasRelatedWork W2125804349 @default.
• W4311754209 hasRelatedWork W2398968602 @default.
• W4311754209 hasRelatedWork W2408534260 @default.
• W4311754209 hasRelatedWork W2789833841 @default.
• W4311754209 hasRelatedWork W2803477235 @default.
• W4311754209 hasRelatedWork W4311754209 @default.
• W4311754209 hasRelatedWork W4318613857 @default.
• W4311754209 hasRelatedWork W2094189570 @default.
• W4311754209 hasVolume "24" @default.
• W4311754209 isParatext "false" @default.
• W4311754209 isRetracted "false" @default.
• W4311754209 workType "article" @default.